candesartan has been researched along with Dyslipidemia in 5 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this study is to assess the effect of the candesartan on the progression of atherosclerosis through the downregulation of NF-κβ and interference with oxidative pathway." | 7.79 | Role of NF-κβ and oxidative pathways in atherosclerosis: cross-talk between dyslipidemia and candesartan. ( Abdulzahra, MS; Al-Amran, FG; Hadi, NR; Majeed, ML; Mohammad, BI; Yousif, MG; Yousif, NG, 2013) |
| " Our aims were to survey the changes in plasma lipid profile in patients with hypertension over a one-year period, and to examine the correlations between these values and the time after the start of ARB monotherapy with candesartan." | 7.76 | Effect of candesartan monotherapy on lipid metabolism in patients with hypertension: a retrospective longitudinal survey using data from electronic medical records. ( Asai, S; Kitamura, N; Nakayama, T; Nishida, Y; Soma, M; Takahashi, Y, 2010) |
| "The objective of this study is to assess the effect of the candesartan on the progression of atherosclerosis through the downregulation of NF-κβ and interference with oxidative pathway." | 3.79 | Role of NF-κβ and oxidative pathways in atherosclerosis: cross-talk between dyslipidemia and candesartan. ( Abdulzahra, MS; Al-Amran, FG; Hadi, NR; Majeed, ML; Mohammad, BI; Yousif, MG; Yousif, NG, 2013) |
| " Our aims were to survey the changes in plasma lipid profile in patients with hypertension over a one-year period, and to examine the correlations between these values and the time after the start of ARB monotherapy with candesartan." | 3.76 | Effect of candesartan monotherapy on lipid metabolism in patients with hypertension: a retrospective longitudinal survey using data from electronic medical records. ( Asai, S; Kitamura, N; Nakayama, T; Nishida, Y; Soma, M; Takahashi, Y, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pais, P | 1 |
| Jung, H | 1 |
| Dans, A | 1 |
| Zhu, J | 1 |
| Liu, L | 1 |
| Kamath, D | 1 |
| Bosch, J | 1 |
| Lonn, E | 1 |
| Yusuf, S | 1 |
| Hadi, NR | 1 |
| Yousif, NG | 1 |
| Abdulzahra, MS | 1 |
| Mohammad, BI | 1 |
| Al-Amran, FG | 1 |
| Majeed, ML | 1 |
| Yousif, MG | 1 |
| Ridker, PM | 1 |
| Nishida, Y | 1 |
| Takahashi, Y | 1 |
| Nakayama, T | 1 |
| Soma, M | 1 |
| Kitamura, N | 1 |
| Asai, S | 1 |
| Chen, J | 1 |
| Li, D | 1 |
| Schaefer, R | 1 |
| Mehta, JL | 1 |
1 trial available for candesartan and Dyslipidemia
| Article | Year |
|---|---|
Impact of blood pressure lowering, cholesterol lowering and their combination in Asians and non-Asians in those without cardiovascular disease: an analysis of the HOPE 3 study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Asia; Asian People; Benzimid | 2019 |
4 other studies available for candesartan and Dyslipidemia
| Article | Year |
|---|---|
Role of NF-κβ and oxidative pathways in atherosclerosis: cross-talk between dyslipidemia and candesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atherosclerosis; Benzimidazoles; Biphenyl Compound | 2013 |
Is Statin Monotherapy the Perfect Polypill?
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Clinical Trial | 2016 |
Effect of candesartan monotherapy on lipid metabolism in patients with hypertension: a retrospective longitudinal survey using data from electronic medical records.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Co | 2010 |
Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis studies with the combined use of rosuvastatin and candesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atherosclerosis; Benzimidazoles; Biphenyl Compound | 2006 |